Rocatinlimab is under clinical development by Kyowa Kirin and currently in Phase III for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase III drugs for Atopic Dermatitis (Atopic Eczema) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Rocatinlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rocatinlimab is under development for the treatment of atopic dermatitis. The drug candidate is a new molecular entity (NME). It is administered through intravenous and subcutaneous infusion. It is a monoclonal antibody and acts by targeting OX40. The drug candidate is based on POTELLIGENT antibody engineering technology. It was also under development for the treatment of moderate plaque psoriasis and ulcerative colitis .
Kyowa Kirin overview
Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, angina pectoris, hypertension, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.
For a complete picture of Rocatinlimab’s drug-specific PTSR and LoA scores, buy the report here.